-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Xylem, Lowers Price Target to $99

Benzinga·10/29/2026 18:48:00
Listen to the news
UBS analyst Joshua Spector maintains Xylem (NYSE:XYL) with a Neutral and lowers the price target from $112 to $99.